TNFRSF18 and neoplasm: Continuously investigating GITR monospecific and bispecific agonists and co-stimulatory GITR ligands in different types of human neoplasms with a high incidence worldwide (e.g., breast and colorectal cancer) has improved our understanding of its potential future use in novel chemotherapy schemas [160,161].